Literature DB >> 27531882

Outcomes after surgical salvage for recurrent oropharyngeal squamous cell carcinoma.

Larissa Sweeny1, Eben L Rosenthal2, Lisa Clemons1, Todd M Stevens3, Eleanor R Cook McIntosh3, William R Carroll4.   

Abstract

OBJECTIVE: Compare human papillomavirus (HPV) status and outcomes in patients undergoing salvage surgical resection for a recurrent oropharyngeal squamous cell carcinoma (OPSCC).
METHODS: Case series with chart review (2005-2013).
RESULTS: Sixty-nine patients were identified who underwent salvage surgical resection for a recurrent OPSCC after primary radiation therapy. There was no difference in the incidence of HPV negative (52%; n=36) and HPV positive (48%; n=33) tumors. The mean time from completion of radiation therapy to salvage surgery was 2.4years. At the time of salvage operation, there was no correlation with HPV status, as assessed by p16 immunohistochemistry, and lymph node metastases (p=0.21), T classification (p=0.22), tracheostomy dependence (p=0.59), gastrostomy tube dependence (p=0.82), or duration from radiation therapy (p=0.63). The majority of patients were either current or former tobacco users (75%) and of the HPV positive patients, 66% were tobacco users. Development of a new recurrence after salvage surgical resection occurred in 33% of patients (n=26), with a higher incidence in patients with HPV negative disease (52%, n=17/33; p=0.05). The overall 2- and 5-year survival rates were 0.47 and 0.23. There was no difference in overall survival rates when stratified by HPV status or tobacco use. Decreased overall 5-year survival rates did correlate with cervical lymph node metastases (p=0.01), advanced tumor stage (p=0.04) and dependence on gastrostomy tube postoperatively (p=0.04).
CONCLUSIONS: This study found cervical lymph node metastases, clinical stage, and dependence on gastrostomy tube for nutrition to have the greatest impact on overall survival for patients with recurrent OPSCC.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HPV; Oropharyngeal cancer; Recurrence; Surgical salvage

Mesh:

Year:  2016        PMID: 27531882     DOI: 10.1016/j.oraloncology.2016.07.006

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  5 in total

1.  What should we expect from robotic surgery for second primary oropharyngeal cancer?

Authors:  Tuan-Jen Fang; Li-Ang Lee; Bing-Shan Huang; Chien-Yu Lin; Cheng-Lung Hsu; Joseph Tung-Chieh Chang; Tzu-Chen Yen; Chun-Ta Liao; Hui-Chen Chiang
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-09       Impact factor: 2.503

2.  High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma.

Authors:  Sulsal Haque; Vidhya Karivedu; Muhammed K Riaz; David Choi; Logan Roof; Sarah Z Hassan; Zheng Zhu; Roman Jandarov; Vinita Takiar; Alice Tang; Trisha Wise-Draper
Journal:  Oral Oncol       Date:  2018-11-16       Impact factor: 5.337

3.  Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522.

Authors:  Elaine O Bigelow; Jonathan Harris; Carole Fakhry; Maura L Gillison; Phuc Felix Nguyen-Tân; David I Rosenthal; Steven J Frank; Suresh G Nair; Houda Bahig; John A Ridge; Jimmy Caudell; Craig Donaldson; Bradley T Clifford; George Shenouda; Michael J Birrer; Yuhchyau Chen; Quynh-Thu Le
Journal:  Head Neck       Date:  2021-11-03       Impact factor: 3.147

4.  Current perspectives on recurrent HPV-mediated oropharyngeal cancer.

Authors:  Theresa Guo; Stephen Y Kang; Ezra E W Cohen
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

Review 5.  The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma.

Authors:  Marc Hamoir; Sandra Schmitz; Carlos Suarez; Primoz Strojan; Kate A Hutcheson; Juan P Rodrigo; William M Mendenhall; Ricard Simo; Nabil F Saba; Anil K D'Cruz; Missak Haigentz; Carol R Bradford; Eric M Genden; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancers (Basel)       Date:  2018-08-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.